Generic Otovel Availability
Last updated on Sep 11, 2024.
Otovel is a brand name of ciprofloxacin/fluocinolone otic, approved by the FDA in the following formulation(s):
OTOVEL (ciprofloxacin hydrochloride; fluocinolone acetonide - solution/drops;otic)
-
Manufacturer: LABORATORIOS SALVAT
Approval date: April 29, 2016
Strength(s): EQ 0.3% BASE;0.025% [RLD]
Has a generic version of Otovel been approved?
An Authorized Generic version of Otovel has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- ciprofloxacin and fluocinolone acetonide AURICULAR (OTIC) SOLUTION .75; .0625 mg/.25mL; mg/.25mL
Xspire Pharma, LLC
NDC Code: 421950128
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Otovel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Patent 8,932,610
Issued: January 13, 2015
Inventor(s): Ruiz I Pol Jaume & Izquierdo Torres Francisca
Assignee(s): Laboratorios Salvat, S.A.A pharmaceutical otic sterile preservative-free composition in the form of a clear aqueous solution comprising 0.01-0.10% (w/v) of Fluocinolone Acetonide, optionally accompanied by 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, a nonionic surfactant, a tonicity adjusting agent and a viscosity increasing agent. It is useful for the prevention and/or treatment of otic inflammation, optionally accompanied by bacterial infection, and for administration from single-use containers.
Patent expiration dates:
- March 24, 2030✓✓
- March 24, 2030
More about Otovel (ciprofloxacin / fluocinolone otic)
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: otic steroids with anti-infectives
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.